Insight Molecular Diagnostics (IMDX) Stock Statistics & Valuation Metrics

Insight Molecular Diagnostics has a market cap or net worth of $74.13M. The enterprise value is $75.80M.

Insight Molecular Diagnostics has 28,619,750 shares outstanding. The number of shares has decreased by -2.65% in one year.

Insight Molecular Diagnostics’s return on equity (ROE) is 4.94 and return on invested capital (ROIC) is -209.76%.

The current PE Ratio of Insight Molecular Diagnostics is ―. Insight Molecular Diagnostics’s PEG ratio is ―.

In the last 12 months, Insight Molecular Diagnostics had revenue of 1.88M and earned -60.66M in profits. Earnings per share was -4.66.

In the last 12 months, operating cash flow was -23.04M and capital expenditures -655.00K, giving a free cash flow of -23.35M billion.

Insight Molecular Diagnostics pays an annual dividend of ―, resulting in a dividend yield of ―

Insight Molecular Diagnostics upcoming earnings date is Nov 6, 2025, After Close (Confirmed).

Insight Molecular Diagnostics as a current ratio of 1.62, with Debt / Equity ratio of 307.29%

In the past 12 months, Insight Molecular Diagnostics has paid 0.00 in taxes.

Insight Molecular Diagnostics EV to EBITDA ratio is -0.44, with an EV/FCF ratio of -1.23.

Insight Molecular Diagnostics has $24.29M in cash and marketable securities with $3.37M in debt, giving a net cash position of -$20.91M billion.

Gross margin is 63.42%, with operating margin of -3245.14%, and net profit margin of -3225.04%.

The average price target for Insight Molecular Diagnostics is $6.13, which is 11.43% higher than the current price. The consensus rating is Moderate Buy